Naoki Okamura, Astellas CEO
Astellas to buy Iveric Bio for $5.9B in cash as biotech awaits August FDA nod in retinal disease
Astellas Pharma will buy New Jersey biotech Iveric Bio for $40 per share in cash, the companies said Sunday night, setting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.